Open help menu
Live Webinar
GXC 2025 Online Virtual Conference - Mental Health Without Borders

Psychedelic Medicine in Action: Rationale and Results of Recent Trials

Robin Carhart-Harris, Ph.D. 🇬🇧
|

Pricing

Information

Date & Time

Learning Objectives

Participants will be able to:

  • Describe the potential of psilocybin therapy to treat anorexia nervosa.

  • Describe the potential of psilocybin therapy to treat fibromyalgia syndrome.

  • Explain the potential of psilocybin therapy to treat depression and compare it to existing treatments.

Educational Goal

This presentation will expand clinicians’ understanding of how psilocybin therapy is being applied in cutting-edge clinical research for conditions such as anorexia nervosa, fibromyalgia, and major depressive disorder. Participants will strengthen their ability to critically evaluate emerging evidence, situate psychedelic treatments within current clinical practices, and consider future applications that may enhance therapeutic outcomes.

Description

In this session, Dr. Robin Carhart-Harris reviews findings from recent clinical trials conducted with colleagues at, or formerly at, Imperial College London.


He will discuss a pilot trial of psilocybin therapy for anorexia nervosa, involving 21 participants with outcomes collected for up to 12 months. The presentation will focus on the study’s motivation, methodology (including MRI and EEG measures), and results, situating them within the broader context of current anorexia treatments and psychedelic medicine research.


He will also present findings from a mechanistic trial of psilocybin therapy in fibromyalgia syndrome, involving 20 participants. The study utilized pre- and post-treatment fMRI along with EEG during dosing sessions. Dr. Carhart-Harris will explain the rationale, findings, and relevance to the broader field of chronic pain treatment.


Additionally, he will review the 2021 New England Journal of Medicine trial comparing psilocybin therapy with escitalopram for major depressive disorder, covering the trial’s inspiration, observations, publication process, and resulting conclusions and future directions.

Target Audience

  • Addiction Professional
  • Counselor
  • Marriage & Family Therapist
  • Nurse
  • Physician
  • Psychologist
  • Social Worker

Presenters

Robin Carhart-Harris, Ph.D. 🇬🇧
Dr Carhart-Harris obtained a PhD in Psychopharmacology from the University of Bristol in 2009 before moving to Imperial College London. There, Prof CH and colleagues completed multimodal human functional neuroimaging studies with LSD, psilocybin, MDMA and DMT, and clinical trials of psilocybin therapy for various disorders, including trials in depression, anorexia and fibromyalgia syndrome. Dr CH founded the Centre for Psychedelic Research at Imperial College London in April 2019 and set up the Carhart-Harris Lab at University of California San Francisco in 2023, where he moved in 2021, becoming the Ralph Metzner Distinguished Professorship in Neurology and Psychiatry at University of California. He spoke at the World Economic Forum (WEF) in Davos in 2019, was listed among the top 31 medical scientists by The Times newspaper in 2020, TIME magazine’s ‘100 Next’ in 2021 and Vox Magazine’s ‘Future 50’ in 2023. His research program at UCSF focuses on the action of psychedelics and psychedelic-therapy. He has published widely, including in top-tier scientific and medical journals and will soon release his first book, entitled: How Psychedelics Work.

Financially Sponsored By

  • GXC Events - The Global Exchange Conference